Defining the toll-like receptor (TLR): type-1 interferon (IFN) pathway in liver disease
Toll-like receptors (TLR) play a crucial role in various inflammatory diseases. TLR constitute the first step in innate immunity by recognizing structurally conserved bacterial and viral components. TLR play a role in the induction of acquired immunity through their involvement in maturation of dendritic cells and by driving a Th1 cell response. Binding of pathogen-specific ligands to TLR in early infection leads to expression of multiple protective cellular genes. The induction of the protective type-1 IFN genes by the activated TLR is mediated by a transcription factor-IFN regulatory factor 3 (IRF-3). Hepatitis C virus (HCV), notorious for its ability to establish persistent infection, is among many viruses that have evolved strategies to block these signaling pathways. Activation of IRF-3 has previously been shown to limit the replication of HCV RNA in cultured hepatocytes, while disruption of these signaling pathways by NS3/4A, an HCV protease, leads to viral persistence. Other protective genes may be involved, but most of these have not been clearly defined.
In a recent article, Li et al 1 showed that NS3/4A causes specific proteolysis of an adaptor protein (TRIF) linking TLR3 to kinases responsible for activating IRF-3 and NF-kB, which consequently blocked the induction of type-1 IFN genes. The cleavage of TRIF by NS3/4A represented a more proximal attack on the pathway before its bifurcation to IRF-3 and NF-kB. This early proteolysis of TRIF inhibited polyI:C-activated signaling through the TLR3 pathway, thereby potentially limiting expression of multiple host defense genes in HCV infection. The authors also concluded that inhibition of the NS3/4A protease by antiviral agents might not only suppress viral replication, but also restore innate antiviral defenses to the virusinfected hepatocytes.
In this issue of Lab Invest, Takii et al 2 demonstrated the importance of an activated TLR3-type-1 IFN signaling pathways in sustaining portal and lobular inflammation in early primary biliary cirrhosis. Type-1 IFN and TLR-3 proteins demonstrable by immunohistochemistry in the portal tracts and liver parenchyma in primary biliary cirrhosis were not observed in chronic hepatitis C and autoimmune hepatitis.
Both studies demonstrate the importance of type-1 IFN induction via the TLR signaling pathways in the inflammatory response of inflammatory liver diseases. Persistent HCV infection occurs when the IFN-signaling pathways are blocked, whereas primary biliary cirrhosis arises in the setting of sustained activation of IFN signaling. Clearly, while inflammatory states in chronic liver disease are critically affected by regulation of IFN signaling pathways, the causal relationships may be quite divergent.
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Gene amplification patterns in human tumorigenesis
The DNA changes that result in tumor formation are highly complex. Genes that relate to tumorigenesis are often divided into oncogenes and tumor suppressor genes. Gene amplification is often necessary for oncogenes to cause tumor formation. The elucidation of these DNA aberrations requires molecular analyses with such techniques as tissue microarrays and fluorescent in situ hybridization (FISH). FISH is based on the complementary doublestranded nature of DNA and the hybridization of specific, fluorescently labeled, DNA-probes. Owing to the relative stability of DNA, determination of gene amplification is possible on archival tissue, making this technique very practical for most practicing pathology departments. Tissue microarrays allow use of one probe to simultaneously evaluate small, representative samples of numerous tumors placed on one slide. In a recent study, Al-Kuraya et al 1 used these techniques to evaluate the amplification pattern of five oncogenes in human breast cancer; HER2, EGFR, MYC, CCND1, and MDM2, and correlated the findings with the clinical follow-up information. The authors created six tissue microarray (TMA) blocks, each of which contained between 342 and 522 'punched out', representative 0.6 mm tissue cylinders. Sections of the TMA blocks were probed for specific genes, using the respective chromosomal centromere regions as a reference. A gene was considered amplified if the ratio of oncogene/ centromere was Z2.0. The frequency of the gene amplifications was 17.3% for HER2, 0.8% for EGFR, 5.3% for MYC, 20.1% for CCND1, and 5.7% for MDM2. All gene amplifications were strongly associated with high tumor grade, while only HER2 amplification was shown to be an independent variable in predicting poor patient outcome. MYC amplifications were almost three times more frequent in medullary cancers. There was also a strong link of HER2 and MYC amplifications to ER/PR negativity. Coamplifications of genes occurred more frequently than expected based on their individual frequencies, suggesting an overall genetic instability among malignant cells. These findings confirmed many other studies regarding HER2 and provided an additional insight on MYC and the genetic instability of breast carcinomas.
Using very similar methodologies and target genes, Tornillo et al, 2 in this issue of Lab Invest, evaluated gastrointestinal stromal tumor gene amplication patterns. These authors found that amplifications were seen in 22% of malignant tumors, nearly 50% of which were MDM2 and CCND1. These studies demonstrate that gene-specific probes applied to large sample sets obtained by tissue microarray, are an effective tool for unlocking the genetic profiles of human neoplasia.
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